Skip to main content

Cardiovascular disorders


10-19-2017 | Vildagliptin | News

Unclear impact of vildagliptin treatment in patients with HF and type 2 diabetes

Results of the VIVIDD trial indicate that it is unclear whether treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin has a beneficial effect on cardiac outcomes among patients with heart failure and type 2 diabetes.

10-18-2017 | Heart failure | News

Glycemic control, drug treatment linked to outcome in patients with HF and type 2 diabetes

Results of a study published in JACC: Heart Failure suggest that glycemic control and drug treatment have complex associations with adverse outcomes among patients with heart failure and type 2 diabetes.

10-11-2017 | Heart failure | News

Sudden death tops CV death causes in type 2 diabetics with atherosclerosis

Sudden death is the most common cause of cardiovascular death among patients with type 2 diabetes and atherosclerotic cardiovascular disease, an analysis of TECOS data shows.

Read more

Related topics



01-13-2017 | Cardiovascular outcomes | Editorial | Article

Clinical implications of cardiovascular outcomes trials in type 2 diabetes

What do the results of CVOTs mean for practicing clinicians? Editorial board member Carol Hatch Wysham reviews the latest evidence and guidelines for reducing CV risk in patients with type 2 diabetes.

Journal articles and book chapters

07-19-2017 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome trial update in diabetes: New evidence, remaining qestions

Seven trials of antihyperglycemic agents from different classes have now been concluded as of May 2017. This review summarizes, compares, and contrasts the key cardiovascular (CV) and non-CV findings from these trials.

Herbst R, Bolton W, Shariff A, Green JB. Curr Diab Rep 2017;17:67. doi:10.1007/s11892-017-0898-8

07-19-2017 | Cardiovascular disorders | Review | Article

Vascular complications in diabetes: Old messages, new thoughts

This review discusses how technological advances, such as genomics, high-resolution imaging, and computational modeling, are providing new opportunities for research on the vascular complications of diabetes.

06-08-2017 | Sodium-glucose co-transporter-2 inhibitors | Review | Article

SGLT2-I in the hospital setting: Diabetic ketoacidosis and other benefits and concerns

Levine et al. cautiously suggest the use of sodium-glucose co-transporter 2 inhibitors in the hospital. However, these must be used judiciously and the practitioner must be aware of euglycemic diabetic ketoacidosis and its risk factors.

Levine JA, Karam SL, Aleppo G. Curr Diab Rep 2017;17:54. doi:10.1007/s11892-017-0874-3

image credits